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We do not see any relevant conflicts. The FLOT65? study [2] compared a triplet versus a doublet combination in older adult patients with gastric cancer, and the statistics and end points of the primary trial are well explained in the methods section of the primary publication. In addition, the FLOT65? study included an add-on quality-of-life (QoL) substudy with its own predefined end points. The primary end point of this QoL substudy [1] was the time to 5 % definitive deterioration of global health status (GHS) from the baseline, on the basis of the TAX 325 trial [3, 4] , as assessed by time-to-event methods (Kaplan-Meier curves). In our article, we focused on the predefined end points of the substudy. The results showed no significant difference between biweekly oxaliplatin therapy plus 5-fluorouracil continuous infusion and folinic acid (FLO) and FLO in combination with docetaxel at 50 mg/m 2 (FLOT) regarding this end point. Hence, our conclusion was that no negative impact of the addition of docetaxel could be demonstrated.
In the primary publication, Al-Batran et al. [2] looked at another measure, which was changes in the global QoL/ GHS score by 10 points or more at 8 weeks, based on data from Osoba et al. [5] . Al-Batran et al. found that more patients experienced such deterioration with the triple therapy. However, in the results section, Al-Batran et al. also indicated there was no significant difference in the mean QoL global health scores between arms.
Hence, the difference in the results in both publications is caused by the different methods used, and this is not unusual in QoL research. All analyses have methodological advantages and disadvantages, the explanation of which would extend beyond this letter. See the discussion section in our article [1] for a comprehensive discussion of this point.
In conclusion, considering the time-to-deterioration analysis and the mean global QoL/GHS scores, our study does not demonstrate a negative impact of the addition of docetaxel to 5-FU and oxaliplatin therapy in older adult patients with gastric cancer.
The primary study was partially funded by SanofiAventis, but the QoL substudy was not. The conflict of interest for Al-Batran and the funding were clearly outlined in the study by Al-Batran et al. [2] .
